Advertisement

Treatment and Outcomes of First Troponin-Negative Non–ST-Segment Elevation Myocardial Infarction

      Little is known about non–ST-segment elevation myocardial infarction (MI) in patients with an initial negative troponin finding. The aim of this study was to determine in post hoc analysis of a large regional medical center presenting clinical characteristics, treatment differences, and in-hospital and 6-month outcomes of first troponin-negative MI (FTNMI). In this study, 659 of 1,855 consecutive patients with non–ST-segment elevation MI (35.5%) were classified as having FTNMI. In-hospital cardiac catheterization rates were similar between the 2 groups (70.1% vs 71.5%, p = 0.53) In hospital, patients with FTNMI were less likely to receive statins (48.9% vs 59.9%, p <0.001). On discharge, patients with FTNMI were less likely to be on clopidogrel (53.1% vs 59.0%, p = 0.019) and statins (67.7% vs 75.2%, p <0.001). At 6-month follow-up, patients with FTNMI were less likely to be on clopidogrel (43.5% vs 55.2%, p = 0.01) In-hospital recurrent ischemia was 2 times as common in FTNMI (20.1% vs 11.5%, p <0.001). There were no differences, however, in congestive heart failure, cardiogenic shock, cardiac arrest, stroke, or death in hospital. At 6 months, patients with FTNMI were 2 times as likely to have had recurrent MI (12.0% vs 6.6%, p <0.001). Combined end points of death at 6 months, MI, stroke, and rehospitalization were higher for FTNMI (47.7% vs 40.9%, p = 0.017); however, this was due to higher rates of recurrent MI. In conclusion, patients with FTNMI received less aggressive pharmacotherapy and were 2 times as likely to have recurrent MI at 6 months. FTNMI is common and represents a clinical entity that should be treated more aggressively.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jernberg T.
        • Lindahl B.
        A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation.
        Am Heart J. 2002; 144: 804-810
        • Keller T.
        • Zeller T.
        • Peetz D.
        • Tzikas S.
        • Roth A.
        • Czyz E.
        • Bickel C.
        • Baldus S.
        • Warnholtz A.
        • Frohlich M.
        • Sinning C.R.
        • Eleftheriadis M.S.
        • Wild P.S.
        • Schnabel R.B.
        • Lubos E.
        • Jachmann N.
        • Genth-Zotz S.
        • Post F.
        • Nicaud V.
        • Tiret L.
        • Lackner K.J.
        • Munzel T.F.
        • Blankenberg S.
        Sensitive troponin I assay in early diagnosis of acute myocardial infarction.
        N Engl J Med. 2009; 361: 868-877
        • Polanczyk C.A.
        • Lee T.H.
        • Cook E.F.
        • Walls R.
        • Wybenga D.
        • Printy-Klein G.
        • Ludwig L.
        • Guldbrandsen G.
        • Johnson P.A.
        Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain.
        J Am Coll Cardiol. 1998; 32: 8-14
        • Januzzi Jr, J.L.
        • Newby L.K.
        • Murphy S.A.
        • Pieper K.
        • Antman E.M.
        • Morrow D.A.
        • Sabatine M.S.
        • Ohman E.M.
        • Cannon C.P.
        • Braunwald E.
        Predicting a late positive serum troponin in initially troponin-negative patients with non–ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies.
        Am Heart J. 2006; 151: 360-366
        • Newby L.K.
        • Christenson R.H.
        • Ohman E.M.
        • Armstrong P.W.
        • Thompson T.D.
        • Lee K.L.
        • Hamm C.W.
        • Katus H.A.
        • Cianciolo C.
        • Granger C.B.
        • Topol E.J.
        • Califf R.M.
        Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes.
        Circulation. 1998; 98: 1853-1859
        • Cannon C.P.
        • Weintraub W.S.
        • Demopoulos L.A.
        • Vicari R.
        • Frey M.J.
        • Lakkis N.
        • Neumann F.J.
        • Robertson D.H.
        • DeLucca P.T.
        • DiBattiste P.M.
        • Gibson C.M.
        • Braunwald E.
        Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
        N Engl J Med. 2001; 344: 1879-1887
        • Chase M.
        • Robey J.L.
        • Zogby K.E.
        • Sease K.L.
        • Shofer F.S.
        • Hollander J.E.
        Prospective validation of the Thrombolysis in Myocardial Infarction Risk Score in the emergency department chest pain population.
        Ann Emerg Med. 2006; 48: 252-259
        • Glaser R.
        • Herrmann H.C.
        • Murphy S.A.
        • Demopoulos L.A.
        • DiBattiste P.M.
        • Cannon C.P.
        • Braunwald E.
        Benefit of an early invasive management strategy in women with acute coronary syndromes.
        JAMA. 2002; 288: 3124-3129
        • Tang E.W.
        • Wong C.K.
        • Herbison P.
        Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome.
        Am Heart J. 2007; 153: 29-35
        • Morrow D.A.
        • Cannon C.P.
        • Rifai N.
        • Frey M.J.
        • Vicari R.
        • Lakkis N.
        • Robertson D.H.
        • Hille D.A.
        • DeLucca P.T.
        • DiBattiste P.M.
        • Demopoulos L.A.
        • Weintraub W.S.
        • Braunwald E.
        Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non–ST elevation myocardial infarction: results from a randomized trial.
        JAMA. 2001; 286: 2405-2412
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • Ganz P.
        • Oliver M.F.
        • Waters D.
        • Zeiher A.
        • Chaitman B.R.
        • Leslie S.
        • Stern T.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Newby L.K.
        • Kristinsson A.
        • Bhapkar M.V.
        • Aylward P.E.
        • Dimas A.P.
        • Klein W.W.
        • McGuire D.K.
        • Moliterno D.J.
        • Verheugt F.W.
        • Weaver W.D.
        • Califf R.M.
        Early statin initiation and outcomes in patients with acute coronary syndromes.
        JAMA. 2002; 287: 3087-3095
        • Nissen S.E.
        Pathobiology, not angiography, should guide management in acute coronary syndrome/non–ST-segment elevation myocardial infarction: the non-interventionist's perspective.
        J Am Coll Cardiol. 2003; 41: 103S-112S
        • Missel E.
        • Mintz G.S.
        • Carlier S.G.
        • Sano K.
        • Qian J.
        • Kaple R.K.
        • Castellanos C.
        • Dangas G.
        • Mehran R.
        • Moses J.W.
        • Stone G.W.
        • Leon M.B.
        Necrotic core and its ratio to dense calcium are predictors of high-risk non–ST-elevation acute coronary syndrome.
        Am J Cardiol. 2008; 101: 573-578
        • Wu X.
        • Maehara A.
        • Mintz G.S.
        • Kubo T.
        • Xu K.
        • Choi S.Y.
        • He Y.
        • Guo N.
        • Moses J.W.
        • Leon M.B.
        • De Bruyne B.
        • Serruys P.W.
        • Stone G.W.
        Virtual histology intravascular ultrasound analysis of non-culprit attenuated plaques detected by grayscale intravascular ultrasound in patients with acute coronary syndromes.
        Am J Cardiol. 2010; 105: 48-53
        • Choi S.H.
        • Chae A.
        • Miller E.
        • Messig M.
        • Ntanios F.
        • DeMaria A.N.
        • Nissen S.E.
        • Witztum J.L.
        • Tsimikas S.
        Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
        J Am Coll Cardiol. 2008; 52: 24-32
        • de Lemos J.A.
        • Blazing M.A.
        • Wiviott S.D.
        • Lewis E.F.
        • Fox K.A.
        • White H.D.
        • Rouleau J.L.
        • Pedersen T.R.
        • Gardner L.H.
        • Mukherjee R.
        • Ramsey K.E.
        • Palmisano J.
        • Bilheimer D.W.
        • Pfeffer M.A.
        • Califf R.M.
        • Braunwald E.
        Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
        JAMA. 2004; 292: 1307-1316
        • Gibson C.M.
        • Pride Y.B.
        • Hochberg C.P.
        • Sloan S.
        • Sabatine M.S.
        • Cannon C.P.
        Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome.
        J Am Coll Cardiol. 2009; 54: 2290-2295
        • Hiro T.
        • Kimura T.
        • Morimoto T.
        • Miyauchi K.
        • Nakagawa Y.
        • Yamagishi M.
        • Ozaki Y.
        • Kimura K.
        • Saito S.
        • Yamaguchi T.
        • Daida H.
        • Matsuzaki M.
        Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).
        J Am Coll Cardiol. 2009; 54: 293-302
        • Qian J.
        • Maehara A.
        • Mintz G.S.
        • Margolis M.P.
        • Biro S.
        • Stone G.W.
        • Leon M.B.
        Relation between individual plaque components and overall plaque burden in the prospective, multicenter virtual histology intravascular ultrasound registry.
        Am J Cardiol. 2009; 104: 501-506
        • Tsimikas S.
        • Witztum J.L.
        • Miller E.R.
        • Sasiela W.J.
        • Szarek M.
        • Olsson A.G.
        • Schwartz G.G.
        High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
        Circulation. 2004; 110: 1406-1412
        • Ho P.M.
        • Fihn S.D.
        • Wang L.
        • Bryson C.L.
        • Lowy E.
        • Maynard C.
        • Magid D.J.
        • Peterson E.D.
        • Jesse R.L.
        • Rumsfeld J.S.
        Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.
        Am Heart J. 2007; 154: 846-851
        • Bilodeau M.L.
        • Simon D.I.
        Clopidogrel for the hot patient.
        Circ Cardiovasc Interv. 2009; 2: 495-496
        • Tricoci P.
        • Roe M.T.
        • Mulgund J.
        • Newby L.K.
        • Smith Jr, S.C.
        • Pollack Jr, C.V.
        • Fintel D.J.
        • Cannon C.P.
        • Bhatt D.L.
        • Gibler W.B.
        • Ohman E.M.
        • Peterson E.D.
        • Harrington R.A.
        Clopidogrel to treat patients with non–ST-segment elevation acute coronary syndromes after hospital discharge.
        Arch Intern Med. 2006; 166: 806-811
        • Budaj A.
        • Yusuf S.
        • Mehta S.R.
        • Fox K.A.
        • Tognoni G.
        • Zhao F.
        • Chrolavicius S.
        • Hunt D.
        • Keltai M.
        • Franzosi M.G.
        Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
        Circulation. 2002; 106: 1622-1626
        • Lewis B.S.
        • Mehta S.R.
        • Fox K.A.
        • Halon D.A.
        • Zhao F.
        • Peters R.J.
        • Keltai M.
        • Budaj A.
        • Yusuf S.
        Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
        Am Heart J. 2005; 150: 1177-1784
        • Serruys P.W.
        • Morice M.C.
        • Kappetein A.P.
        • Colombo A.
        • Holmes D.R.
        • Mack M.J.
        • Stahle E.
        • Feldman T.E.
        • van den Brand M.
        • Bass E.J.
        • Van Dyck N.
        • Leadley K.
        • Dawkins K.D.
        • Mohr F.W.
        Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
        N Engl J Med. 2009; 360: 961-972
        • Movahed M.R.
        • John J.
        • Hashemzadeh M.
        • Jamal M.M.
        Trends in the age adjusted mortality from acute ST segment elevation myocardial infarction in the United States (1988–2004) based on race, gender, infarct location and comorbidities.
        Am J Cardiol. 2009; 104: 1030-1034